(Q35692680)

9 August 2017

1 reference

title

Pharmacogenetics in the treatment of breast cancer (English)

1 reference

9 August 2017

Stearns V

1

1 reference

9 August 2017

Davidson NE

series ordinal

2

1 reference

9 August 2017

Flockhart DA

series ordinal

3

1 reference

9 August 2017

publication date

1 January 2004

1 reference

The Pharmacogenomics Journal

9 August 2017

published in

1 reference

9 August 2017

volume

4

1 reference

9 August 2017

issue

3

1 reference

9 August 2017

page(s)

143-153

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.tpj.6500242

9 August 2017

exact match

0 references

cites work

Inheritance and drug response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Pharmacogenomics--drug disposition, drug targets, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Welcome to the genomic era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

New prognostic factors for breast cancer recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Increased expression of estrogen-receptor exon-5-deletion variant in relapse tissues of human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Overview of the main outcomes in breast-cancer prevention trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

The pharmacology and clinical uses of tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Influence of adjuvant tamoxifen treatment on bone mineral density and bone turnover markers in postmenopausal breast cancer patients in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Aromatase inhibitors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Relation of aromatase gene polymorphism and hormone replacement therapy to serum estradiol levels, bone mineral density, and fracture risk in early postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Polymorphisms in the CYP19 and AR genes--relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy: The Danish Osteoporosis Prevention Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Polymorphisms in steroid hormone pathway genes and mammographic density

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Genetic predisposition and treatment-related leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Polymorphisms of drug metabolizing enzymes and markers of genotoxicity to identify patients with Hodgkin's lymphoma at risk of treatment-related complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Mutation of the class I beta-tubulin gene does not predict response to paclitaxel for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Clinical pharmacokinetics of docetaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Noninvasive tests of CYP3A enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

CYP3A4 and the erythromycin breath test

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Thymidylate synthase as a translational regulator of cellular gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Role in translation of a triple tandemly repeated sequence in the 5'-untranslated region of human thymidylate synthase mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Distinct prevalence of the CYP19 Δ3(TTTA)7 allele in premenopausal versus postmenopausal breast cancer patients, but not in control individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

7 January 2021

Tamoxifen in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

7 January 2021

Endometrial carcinoma in tamoxifen-treated breast cancer patient: clinicopathological, immunohistochemical, and genetic analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

7 January 2021

Quality of health care delivered to adults in the United States

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

7 January 2021

Genetic variants of CYP19 (aromatase) and breast cancer risk

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

7 January 2021

Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

7 January 2021

Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

7 January 2021

MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

7 January 2021

CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

7 January 2021

Cytochrome P450 3A pharmacogenetics: the road that needs traveled

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

7 January 2021

Functional Analysis and DNA Polymorphism of the Tandemly Repeated Sequences in the 5'-terminal Regulatory Region of the Human Gene for Thymidylate Synthase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

7 January 2021

Novel thymidylate synthase enhancer region alleles in African populations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500242

7 January 2021

Identifiers

DOI

10.1038/SJ.TPJ.6500242

1 reference

Dimensions Publication ID

9 August 2017

1023887500

0 references

1 reference